Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Awesome day for MIR! Expecting some really good news here.
$mir $0.445 ^ 0.065 (17.11%)
Volume: 4,061,449 @07/03/20 4:28:27 PM EDT
THERE IS NO NEWS --and no further developments---a ponzee play again
yup, PUMPER-dumpers are at it again--thanks to the covid
now in the 30's
wont buy any until a steady up-grade
Somethings brewing, news halted pending great news, UP UP AND AWAY !!
Once the FDA approves this, easily triple coming in the price, kicking myself, I bought in at 9 cents, and spread my stock picks out, wished I had gone all in on this one, up 650 % in 1 1/2 months !!!!!
now in the 50's
the buyers money is used to prop up the pps
works as long as the buyers keep buying
well it could , but its big run in the 90's was about 78 cents---due to some virus or Ebola
all depends on what people will pay
Awesome Ride !!!!! Makings of a historic run 9 - 45 cents in a month could this run to $ 3-5 , looking like it's going to happen with the right news !!!!
was all that confirmed by talking to the I.R. Rep
consider that denturist in Halifax was shorting MIR for the last 15 years
This stock is exploding, wait till it gets the NATIONAL RECOGNITION it deserves and the world reaches out for this INSTANT RESULT TESTING KIT
No other company can say this, no waiting around, just imagine the possibilities, airports, hospitals, anywhere there are people this test is needed.
MIR.VN - Analysis (Rating)
Each investor clearly must make his / her own educated decision and calculate their own personal financial risk. A useful aid in this process is BARCHART. Barchart offers both a free and premium paid service. I am in no way affiliated nor do I receive compensation in any way from this service. I, like most on this board, strive to receive credible non-biased insight as to the true validity / valuation of stock price, positioning, etc. This has proven to be particularly useful during the global covid pandemic.
BarChart Analysis: MIR.VN
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
STRENGTH: TOP 1%
DIRECTION: TOP 1%
Well, I'm okay with just me and Calgary here, that's tooooootally fine!! :) :)
I know, the best testing kit coming to the market and no one talking about it.
Can you believe these boards are empty??
I am utterly astounded that both this board and the MMIRF board are quiet!! I mean, it's fine by me, but iHub where you at?? Lol :)
This is skyrocking !!! 6 cents to 21 cents in 3 days, fastest test in the world for covid instant results, this is what is needed and demanded by all the world's governments to get back to running their economies
This company is heading in the right direction on all fronts, millions of tests coming $$$$ millions of dollars for the testing coming to the company this will easily pass the $1 mark in the very near future,
USE THE MMIRF BOARD
Highly recommending using the MMIRF Board to discuss Medmira
https://investorshub.advfn.com/MedMira-Inc-MMIRF-31795/
Am not mad, just Jealous...……….GLTA
$mir MedMira Reports Second Quarter Results FY2020
Halifax, Nova Scotia, March 31, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2020.
Profit and Loss Highlights
• Revenue: The Company recorded revenues in Q2 FY2020 of $95,012 compared to $129,990 in Q2 FY2019. The decrease of these revenues was due a change in ordering patterns by the Company’s main customer.
• Gross Profit: The Company recorded a gross profit in Q1 FY2020 of $79,213 compared to $104,411 for the same period last year. The overall gross margin percentage on sales increased by 3% from 80% in Q2 FY2019 to 83% in this financial quarter.
• Operating expenses: The Company recorded for this quarter operating expenses of $511,761 compared to $477,715 in Q2 FY2019. The increase of 7% in operating expenses was primarily due to additional costs for regulatory work.
• Net loss: The Company recorded a net loss of $614,306 compared to $593,320 in Q1 FY2019. The increase of 3% is due to additional cost for regulatory work.
Balance Sheet Highlights
• Assets: The Company had an increase of its assets by $167,530 compared to last quarter due to an increase in cash and receivables.
• Liabilities: The Company’s liabilities increased by $781,836 between Q1 FY2020 and Q2 FY2020. The Company’s current liabilities increased by $819,726 or 6% due to loans provided to the Company.
• Loans in default increased by $578,222 or 7% compared to last quarter. All long and short terms debts are currently classified as in default due to the continuing debt restructuring negotiations.
• Working Capital deficit: As a result of the increases noted above, the Company recorded higher working capital deficit of $606,143 or 4% compared to last quarter.
The Company’s financial statements and management’s discussion and analysis are available on the Company’s profile on SEDAR at www.sedar.com. For matters of going concern, reference is made to the Auditor’s Emphasis of Matter statement in the fiscal year ended 2019 Auditors Report and note 2b in the audited financial statements which is also available on SEDAR.
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF) TechnologyTM. The Company’s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal, Multiplo and MiriadTM brands in global markets. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Contacts:
Markus Meile, CFO
Tel: 902-450-1588 Email: ir@medmira.com
$mir MedMira Announces Update on Development of Point-of-Care Antibody Test
Halifax, Nova Scotia, 15th of April, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID- 19TM delivers immediate results without the need for any additional equipment such as a reader or a timer. The product is subject to obtaining regulatory approvals to sell in the selected markets. MedMira’s aim is to provide a reliable screening tool to relieve overburdened healthcare providers allowing for faster turn-around times with a rapid and reliable testing solution.
http://medmira.com/wp-content/uploads/2020/04/PR_SARS-CoV-2_April-17.pdf
what goes around -0--comes around----missed the boat
https://player.vimeo.com/video/243016672
it ran past my bid of 5 cents---I don't chase those pumpers....its good for the company---they should show better results next.
4/16/2020
MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID-19TM delivers immediate results without the need for any additional equipment such as a reader or a timer.
What do you think of todays news will she run?
some activity due to virus-and flu epidemic---might hit .03 and 5yr high of .05
this company is always juggling the books so as not to pay tax---ps do not tick the tax man off
200% rise till some farmer hauled a load away , reducing to 100% gain
during the dot com bubble, the company was awash with money from the HIV crisis, now its struggling with new concepts in health care for the ageing population
C : MIR
Shares Issued 658,364,320
Close 2018-08-29 C$ 0.015
Medmira ---HALTED--- News better be good !!!!
or My friend will turn out the lights https://player.vimeo.com/video/243016672
Mir has major news coming
followed by big bio techs
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
94
|
Created
|
01/13/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |